STAT5h
Schizophrenia drug AbbVie picked up in $9 billion acquisition fails in key trials
AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a ...
AbbVie's closely watched schizophrenia drug fails two studies, shares slide
AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...
AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with ...